Skip to main content
Erschienen in: Clinical and Experimental Nephrology 5/2016

20.11.2015 | Original Article

Risk factors associated with relapse or infectious complications in Japanese patients with microscopic polyangiitis

verfasst von: Kiyoki Kitagawa, Kengo Furuichi, Akihiro Sagara, Yasuyuki Shinozaki, Shinji Kitajima, Tadashi Toyama, Akinori Hara, Yasunori Iwata, Norihiko Sakai, Miho Shimizu, Shuichi Kaneko, Takashi Wada, Kanazawa Study Group for Renal Diseases and Hypertension

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

The prevention of relapse and infection complications during remission maintenance therapy is required to improve the prognosis of patients with microscopic polyangiitis (MPA) showing rapidly progressive glomerulonephritis (RPGN). The clinicopathological characteristics of patients with ANCA-positive MPA were examined to determine the risk factors for relapse or infectious complications after remission induction therapy.

Patients and methods

The study population consisted of 52 patients diagnosed as ANCA-positive MPA showing RPGN from 2002 to 2012, after publication of the Japanese guideline for RPGN. The clinicopathological findings were examined between the presence and absence of relapse or infectious complications.

Results

The value of vasculitis damage index (VDI) was high for the relapse group and VDI value was identified as the leading factor associated with relapse [hazard ratio (HR) 3.36, 95 % confidence interval (CI) 1.58–7.12, P < 0.01]. On the other hand, the values of Birmingham Vasculitis Activity Score, clinical grade category of RPGN at diagnosis, and VDI at remission were high in the infectious group. Furthermore, clinical grade category of RPGN was the leading factor associated with infectious complications (HR 5.30, 95 % CI 1.41–19.9, P = 0.01).

Conclusion

The disease activity at diagnosis and severity of organ damage at remission were associated with relapse and infectious complications during remission maintenance therapy and infectious complication affected kidney survival and all-cause mortality in patients with ANCA-positive MPA exhibiting RPGN.
Literatur
1.
Zurück zum Zitat Churg J, Bernstein J, Glassock RJ. Classification of glomerular disease. In: Churg J, Bernstein J, Glassock RJ editors. Renal disease classification and atlas of glomerular diseases, 2nd ed. New York; 1995. p. 11. Churg J, Bernstein J, Glassock RJ. Classification of glomerular disease. In: Churg J, Bernstein J, Glassock RJ editors. Renal disease classification and atlas of glomerular diseases, 2nd ed. New York; 1995. p. 11.
2.
Zurück zum Zitat Kitagawa K, Furuichi K, Shinozaki Y, Toyama T, Kitajima S, Hara A, et al. Long-term observations of clinicopathological characteristics and outcome of Japanese patients with pauci-immune crescentic glomerulonephritis. Clin Exp Nephrol. 2013;17:858–65.CrossRefPubMed Kitagawa K, Furuichi K, Shinozaki Y, Toyama T, Kitajima S, Hara A, et al. Long-term observations of clinicopathological characteristics and outcome of Japanese patients with pauci-immune crescentic glomerulonephritis. Clin Exp Nephrol. 2013;17:858–65.CrossRefPubMed
3.
Zurück zum Zitat Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.CrossRefPubMed Koyama A, Yamagata K, Makino H, Arimura Y, Wada T, Nitta K, et al. A nationwide survey of rapidly progressive glomerulonephritis in Japan: etiology, prognosis and treatment diversity. Clin Exp Nephrol. 2009;13:633–50.CrossRefPubMed
4.
Zurück zum Zitat Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res. 2010;62:1166–73.CrossRef Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res. 2010;62:1166–73.CrossRef
5.
Zurück zum Zitat Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56:87–96.CrossRefPubMed Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007;56:87–96.CrossRefPubMed
6.
Zurück zum Zitat Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman K, Luqmani R. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66:283–92.PubMed Flossmann O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, Westman K, Luqmani R. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;66:283–92.PubMed
7.
Zurück zum Zitat Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371–80.CrossRefPubMed Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, Adu D. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40:371–80.CrossRefPubMed
8.
Zurück zum Zitat Wada T, Hara A, Arimura Y, Sada K-E, Makino H. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol. 2012;39:545–51.CrossRefPubMed Wada T, Hara A, Arimura Y, Sada K-E, Makino H. Risk factors associated with relapse in Japanese patients with microscopic polyangiitis. J Rheumatol. 2012;39:545–51.CrossRefPubMed
9.
Zurück zum Zitat Kitajima S, Furuichi K, Sakai N, Sagara A, Shinozaki Y, Toyama T, et al. Relapse and its remission in Japanese patients with idiopathic membranous nephropathy. Clin Exp Nephrol. 2015;19:278–83.CrossRefPubMed Kitajima S, Furuichi K, Sakai N, Sagara A, Shinozaki Y, Toyama T, et al. Relapse and its remission in Japanese patients with idiopathic membranous nephropathy. Clin Exp Nephrol. 2015;19:278–83.CrossRefPubMed
10.
Zurück zum Zitat Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–7.CrossRefPubMed Mukhtyar C, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis. 2009;68:310–7.CrossRefPubMed
11.
Zurück zum Zitat Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology. 2007;46:v1615–6.CrossRef Lapraik C, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology. 2007;46:v1615–6.CrossRef
12.
Zurück zum Zitat Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2012;22:394–404.CrossRefPubMed Ozaki S, Atsumi T, Hayashi T, Ishizu A, Kobayashi S, Kumagai S, et al. Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis: the JMAAV study. Mod Rheumatol. 2012;22:394–404.CrossRefPubMed
13.
Zurück zum Zitat Ito-Ihara T, Ono T, Nogaki F, Suyama K, Tanaka M, Yonemoto S, et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract. 2006;102:c35–42.CrossRefPubMed Ito-Ihara T, Ono T, Nogaki F, Suyama K, Tanaka M, Yonemoto S, et al. Clinical efficacy of intravenous immunoglobulin for patients with MPO-ANCA-associated rapidly progressive glomerulonephritis. Nephron Clin Pract. 2006;102:c35–42.CrossRefPubMed
14.
Zurück zum Zitat Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58:308–17.CrossRefPubMed Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58:308–17.CrossRefPubMed
15.
Zurück zum Zitat Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180–8.CrossRefPubMed Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180–8.CrossRefPubMed
16.
Zurück zum Zitat Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosis—a clinical randomized controlled trial. Nephrol Dial Transplant. 2011;26:206–13.CrossRefPubMed Szpirt WM, Heaf JG, Petersen J. Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener’s granulomatosis—a clinical randomized controlled trial. Nephrol Dial Transplant. 2011;26:206–13.CrossRefPubMed
17.
Zurück zum Zitat Hasegawa M, Ohashi A, Kabutan N, Hiramatsu S, Kato M, Murakami K, et al. Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis: a pilot study of 21 patients. Ther Apher Dial. 2006;10:412–8.CrossRefPubMed Hasegawa M, Ohashi A, Kabutan N, Hiramatsu S, Kato M, Murakami K, et al. Cytapheresis for the treatment of myeloperoxidase antineutrophil cytoplasmic autoantibody-associated vasculitis: a pilot study of 21 patients. Ther Apher Dial. 2006;10:412–8.CrossRefPubMed
Metadaten
Titel
Risk factors associated with relapse or infectious complications in Japanese patients with microscopic polyangiitis
verfasst von
Kiyoki Kitagawa
Kengo Furuichi
Akihiro Sagara
Yasuyuki Shinozaki
Shinji Kitajima
Tadashi Toyama
Akinori Hara
Yasunori Iwata
Norihiko Sakai
Miho Shimizu
Shuichi Kaneko
Takashi Wada
Kanazawa Study Group for Renal Diseases and Hypertension
Publikationsdatum
20.11.2015
Verlag
Springer Japan
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 5/2016
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-015-1199-7

Weitere Artikel der Ausgabe 5/2016

Clinical and Experimental Nephrology 5/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.